In a prospective study in 107 T2DM patients with stage 2–3 CKD, higher serum FGF-23 levels were associated with increased risk for hospitalization for cardiovascular events and higher cardiovascular mortality [88]. This evidence concerns the gene FGF23 and chronic kidney disease.